drugset / Trial / NCT01921790
Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma
Phase 2
Unknown
30 enrolled
Sun Yat-sen University
Eli Lilly and Company · collabHoffmann-La Roche · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of avastin combined with gemcitabine, oxaliplatin, pegaspargase and dexamethasone(Avastin+ GemAOD) as first-line treatment in patients with untreated natural killer(NK)/T cell lymphoma
Timeline
- Start
- 2013-08
- Primary completion
- 2015-08
- Completion
- 2020-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Dexamethasone | Small molecule | 20 mg | Intravenous |
| Subject | Gemcitabine | Small molecule | 1 g | Intravenous |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Subject | Pegaspargase | Protein / enzyme biologic | 2500 iu | Intramuscular |